植物生物活性化合物作为帕金森病治疗药物的新兴作用
Nitu Kumari1, Santosh Anand1, Kamal Shah2
1Department of Biotechnology, School of Applied Sciences, REVA University, Bengaluru 560064, Karnataka, India.
Molecules (Basel, Switzerland)
|November 25, 2023
概括
药用植物和天然化合物在帕金森病 (PD) 管理方面表现有前途. 研究强调了多,烯和类的治疗潜力,以对抗神经退行.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 包括帕金森病 (PD) 在内的神经系统疾病影响全球约10亿人.
- 脊髓病是一种主要的神经退行性疾病,其结果是多巴胺基神经元损失,导致运动和认知障碍.
- 目前的PD治疗提供了症状缓解,需要对新型治疗剂进行研究.
研究的目的:
- 审查最近 (2019-2023) 对药用植物,草药配方和植物衍生生物活性分子用于PD管理的研究.
- 阐明这些天然化合物的作用机制,重点关注多,烯和化物.
- 确定潜在的治疗药物,提高了PD的特异性,目标可接近性,生物可用性和安全性.
主要方法:
- 关于体外,体内和体内研究的综合文献综述.
- 专注于最近调查的 (2019-2023) 药用植物,草药配方和生物活性化合物.
- 对植物生物活性物质的抗炎,抗氧化和神经保护性质的分析.
主要成果:
- 药用植物,草药配方和多,烯和类等生物活性物体对PD具有显著的治疗潜力.
- 这些天然化合物具有强大的抗炎,抗氧化和促进大脑健康的特性.
- 证据支持它们在临床前和in silico模型中的有效性,用于管理PD症状和进展.
结论:
- 药用植物及其生物活性成分为开发新型,更安全的帕金森病治疗方法提供了有希望的途径.
- 进一步的研究可以带来增值配方和营养药,以有效管理PD.
- 自然化合物为传统疗法提供了潜在的替代品或辅助剂,并提高了宿主安全性.
相关概念视频
01:24Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
01:15Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195